MedTrace Logo

CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

NCT03508635 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2019-08-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the dose-related safety, tolerability, pharmacokinetics (PK) and pharmacological effects (PD) of CORT125134 and its active metabolite CORT125201 after single and multiple ascending oral doses of CORT125134 in healthy participants.

Conditions

  • Healthy

Interventions

DRUG

CORT125134

Oral capsules

DRUG

Matching Placebo of CORT125134

Placebo

DRUG

Mifepristone

Active comparator

DRUG

Prednisone

Challenge agent

DRUG

Glucose

Sponsors & Collaborators

  • Corcept Therapeutics

    lead INDUSTRY

Principal Investigators

  • Pui Leung · Quotient Clinical

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03508635 on ClinicalTrials.gov